221 related articles for article (PubMed ID: 31387520)
1. Identification of potential binding pocket on viral oncoprotein HPV16 E6: a promising anti-cancer target for small molecule drug discovery.
Kolluru S; Momoh R; Lin L; Mallareddy JR; Krstenansky JL
BMC Mol Cell Biol; 2019 Aug; 20(1):30. PubMed ID: 31387520
[TBL] [Abstract][Full Text] [Related]
2. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.
Yuan CH; Filippova M; Tungteakkhun SS; Duerksen-Hughes PJ; Krstenansky JL
Bioorg Med Chem Lett; 2012 Mar; 22(5):2125-9. PubMed ID: 22300659
[TBL] [Abstract][Full Text] [Related]
4. An in silico appraisal of azoic and disulphide derivatives for anticancer activity against HPV E6 oncoprotein to medicate cervical cancer.
Choudhury AD; Choudhury MD; Chetia P; Chowdhury A; Talukdar AD
Comb Chem High Throughput Screen; 2014 Jan; 17(1):38-46. PubMed ID: 24164050
[TBL] [Abstract][Full Text] [Related]
5. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
6. Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cells.
Yuan CH; Filippova M; Krstenansky JL; Duerksen-Hughes PJ
Cell Death Dis; 2016 Jan; 7(1):2060. PubMed ID: 26794656
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening for Potential Inhibitors of High-Risk Human Papillomavirus 16 E6 Protein.
Kumar S; Jena L; Mohod K; Daf S; Varma AK
Interdiscip Sci; 2015 Jun; 7(2):136-42. PubMed ID: 26199214
[TBL] [Abstract][Full Text] [Related]
8. Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors.
Rietz A; Petrov DP; Bartolowits M; DeSmet M; Davisson VJ; Androphy EJ
PLoS One; 2016; 11(2):e0149845. PubMed ID: 26915086
[TBL] [Abstract][Full Text] [Related]
9. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of structural changes in human papillomavirus type 16 (HPV16) E6 oncoprotein and its variants.
Rodríguez-Ruiz HA; Garibay-Cerdenares OL; Illades-Aguiar B; Montaño S; Jiang X; Leyva-Vázquez MA
BMC Mol Cell Biol; 2019 Aug; 20(1):35. PubMed ID: 31426742
[TBL] [Abstract][Full Text] [Related]
11. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
12. Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues.
Malik RM; Fazal S; Kamal MA
Protein Pept Lett; 2021; 28(4):414-425. PubMed ID: 32703126
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.
Butz K; Denk C; Ullmann A; Scheffner M; Hoppe-Seyler F
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6693-7. PubMed ID: 10829072
[TBL] [Abstract][Full Text] [Related]
14. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
16. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
17. Structural and biochemical analysis of the PTPN4 PDZ domain bound to the C-terminal tail of the human papillomavirus E6 oncoprotein.
Lee HS; Yun HY; Lee EW; Shin HC; Kim SJ; Ku B
J Microbiol; 2022 Apr; 60(4):395-401. PubMed ID: 35089587
[TBL] [Abstract][Full Text] [Related]
18. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
[TBL] [Abstract][Full Text] [Related]
19. Transactivation activity of human papillomavirus type 16 E6*I on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells.
Wanichwatanadecha P; Sirisrimangkorn S; Kaewprag J; Ponglikitmongkol M
J Gen Virol; 2012 May; 93(Pt 5):1081-1092. PubMed ID: 22278827
[TBL] [Abstract][Full Text] [Related]
20. USP15 inhibits HPV16 E6 degradation and catalytically inactive USP15 has reduced inhibitory activity.
Yaginuma Y; Yoshimoto M; Tokuda A
Acta Virol; 2018; 62(2):147-156. PubMed ID: 29895155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
